A case report, however, suggested the possibility of pNEC with activating the KRAS mutation and aberrant expressions of TP53 and SMAD4, and Hijioka et al. found that the KRAS mutation was present in over 80% of cases of poorly differentiated NEC [36,40]. This evidence concerns the gene KRAS and neuroendocrine carcinoma.